Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition
Status:
Terminated
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
1- Proportion of patients with mean daily glycemia <140mg/dL during the period of 7 days of
treatment with glargine plus supplemental glulisine versus patients with glulisine sliding
scale.
Secondary Objective:
1. Incidence of moderate hyperglycemia (>140mg/dL) during the treatment period.
2. Incidence of hypoglycemia (<60mg/dL and < 40mg/dL) during the treatment period.
3. Incidence of severe hyperglycemia (>400mg/dL) during the treatment period.
4. Total dose of insulin and correction dose in each group.